Table 1.
Clinicopathological characteristics and outcomes of 15 urothelial carcinoma patients subject to CTOS assay
| Patient # | Age, sex | Pathology, disease stage | Establishment of CTOS (>20 spheres) | Sensivity |
|---|---|---|---|---|
| #01 | 83, M | HG, >pT2 | No | – |
| #02 | 82, M | LG (G1), pTa | Yes | No |
| #03 | 75, F | HG with squamous dif., pTa | No | – |
| #04 | 69, M | HG (G2 > 3), pT1 | No | – |
| #05 | 76, M | HG (G2), pTa | Yes | CDDP + DSF |
| #06 | 76, M | HG (G2), pTa | No | – |
| #07 | 81, M | HG (G3), >pT2 | No | – |
| #08 | 81, F | HG (G3), >pT1 | No | – |
| #09 | 47, M | HG (G3), pT2 | Yes | CDDP + DSF |
| #10 | 49, M | HG (G3), >pT1 | No | – |
| #11 | 92, M | HG (G2 > G3), pT1 | No | – |
| #12 | 74, M | HG (G3), pT1 | Yes | CDDP alone, CDDP + DSF |
| #13 | 87, M | HG, pT1 | No | – |
| #14 | 69, M | HG (G2), pTa | Yes | CDDP + DSF |
| #15 | 80, M | HG (G2), pT1 | Yes | CDDP + DSF |
HG high grade, LG low grade, CDDP cisplatin, DSF disulfiram